Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Abstract

BACKGROUND Hyponatremia (serum sodium concentration, <135 mmol per liter) is a predictor of death among patients with chronic heart failure and cirrhosis. At present, therapy for acute and chronic hyponatremia is often ineffective and poorly tolerated. We investigated whether tolvaptan, an orally active vasopressin V(2)-receptor antagonist that promotes… (More)
View Slides

Topics

4 Figures and Tables

Cite this paper

@article{Schrier2006TolvaptanAS, title={Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.}, author={Robert Schrier and Peter Gross and Mihai Gheorghiade and Tom{\'a}s Berl and Joseph G. Verbalis and Frank S. Czerwiec and Cesare Orlandi}, journal={The New England journal of medicine}, year={2006}, volume={355 20}, pages={2099-112} }